Halawa Alaa 4

What Happened

• Halawa Alaa, a director of Neumora Therapeutics (NMRA), was granted a derivative award covering 80,000 shares on May 27, 2026. The Form 4 lists an acquisition price of $0.00 per share (reported as a derivative grant), so no cash payment is shown on the form. This is an award/grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29 (filed within the typical 2-business-day window).
• Amount: 80,000 shares (derivative security); reported acquisition price $0.00 per share.
• Shares owned after transaction: Not specified in the filing.
• Footnote: F1 — 100% of the shares subject to the option vest on the earlier of (i) the one-year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
• No sale or exercise was reported; this is a grant/award (transaction code A).

Context

• This filing reports a grant of a derivative award (an option-like award per the footnote). Such awards do not represent immediate cash or market sales and are subject to vesting—meaning the holder cannot immediately sell the underlying shares until vesting (and any exercise, if required). The filing shows no immediate disposition or exercise.